HACKENSACK, N.J., Oct. 16, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Champions' TumorGrafts® are the subject of presentations at the Connective Tissue Oncology Society Annual Meeting and the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Connective Tissue Oncology Society Annual Meeting (October 15-18, Berlin)
Title: Individualizing Therapeutic Approaches: The Use of Patient-Derived Xenograft (PDX) Models to Predict Patient Response to Therapy in Pediatric Sarcoma
Abstract: 2048726
Title: A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX) Modeling in Patients with Metastatic or Recurrent Sarcoma: Study Design and Rationale
Abstract: 2048742
Presentation Date/Time: October 16, 5:30 p.m. CEST
Location: InterContinental Berlin Hotel, Potsdam II & IV
2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (October 30-November 1, Chicago)
Title: The Use Of Patient-derived Xenograft (PDX) Models To Predict Patient Response In Non-small Cell Lung Cancer (NSCLC)
Abstract: 3332
Presentation Date/Time: October 30, 5:00 p.m. CDT
Location: Chicago Marriott Downtown Magnificent Mile
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.
SOURCE Champions Oncology, Inc.
